Skip to content
Back to Blog
Bio
2025-11-089 min read29

Bio Company Overseas Expansion and Regulatory Strategy

Strategies for Korean bio companies looking to expand internationally, including navigating diverse regulatory frameworks across major markets.

KITIM Consulting Team

Bio Company Overseas Expansion and Regulatory Strategy

For Korean bio companies, international expansion represents both a significant growth opportunity and a complex strategic challenge. Each major market has its own regulatory framework, competitive dynamics, and commercial requirements. A well-planned expansion strategy that addresses regulatory, commercial, and operational considerations is essential for success.

Global Market Opportunity

  • United States: The world's largest pharmaceutical market, representing approximately 40% of global pharmaceutical revenue. High pricing potential but complex regulatory and commercial requirements
  • European Union: A large, unified regulatory market of over 400 million people, though individual country pricing and reimbursement systems add complexity
  • Japan: The third-largest pharmaceutical market globally, with unique regulatory requirements and a strong preference for local clinical data
  • Southeast Asia: Rapidly growing markets with increasing healthcare spending, though regulatory systems vary significantly between countries
  • China: Massive market potential with a reformed regulatory system (NMPA), though geopolitical and IP protection concerns require careful navigation
  • Regulatory Strategy by Region

    FDA pathway (United States):

  • Pre-IND meetings to align development strategy with FDA expectations
  • IND application for clinical trial authorization
  • Breakthrough Therapy, Fast Track, and Priority Review designations for qualifying programs
  • NDA/BLA submission with potential for accelerated approval in serious conditions
  • Engage experienced US regulatory consultants early in the process
  • EMA centralized and decentralized procedures (Europe):

  • Centralized procedure for biotechnology products, providing marketing authorization valid across all EU member states
  • Decentralized procedure for products not requiring centralized authorization, allowing simultaneous review in multiple member states
  • Scientific advice from EMA to confirm development strategy
  • Pediatric Investigation Plans required for most new applications
  • PMDA pathway (Japan):

  • Consultation system (pre-application meetings) to discuss development and regulatory strategy
  • Preference for bridging studies with Japanese patients when relying primarily on foreign clinical data
  • Sakigake designation for innovative products with priority review
  • PMDA increasingly accepts multi-regional clinical trial data meeting ICH E5 guidelines
  • Market Entry Models

  • Direct entry: Establishing your own commercial operations in the target market provides maximum control but requires significant investment in local infrastructure, talent, and regulatory capabilities
  • Partnership: Licensing or co-development agreements with established local partners provide market access while sharing risk and leveraging partner expertise
  • Out-licensing: Licensing your product to a partner for development and commercialization in specific territories, receiving upfront payments, milestones, and royalties while reducing operational burden
  • Subsidiary with distributor: Establishing a local subsidiary for regulatory affairs while contracting distribution to an experienced partner, balancing control with operational efficiency
  • Key Considerations

    Successful overseas expansion requires attention to several critical factors:

  • Cultural differences: Business practices, negotiation styles, and decision-making processes vary significantly across markets. Invest in cultural intelligence and local expertise
  • Pricing and reimbursement: Each market has unique pricing and reimbursement systems. Early engagement with health technology assessment bodies and pricing authorities is essential for commercial success
  • Local regulations: Beyond drug approval, consider local manufacturing requirements, labeling regulations, pharmacovigilance obligations, and data privacy laws
  • Intellectual property: Patent filing strategies must be coordinated across target markets, and local IP enforcement mechanisms should be understood before market entry
  • Talent acquisition: Building a team with local language skills, regulatory expertise, and commercial networks is crucial for sustained success
  • Government Support for Bio Export

    Korean bio companies can access several government programs supporting international expansion:

  • KOTRA: The Korea Trade-Investment Promotion Agency provides market research, buyer matching, trade fair participation support, and overseas office infrastructure for Korean companies entering new markets
  • KHIDI international programs: The Korea Health Industry Development Institute offers programs specifically supporting bio/health company internationalization, including regulatory consulting and clinical trial coordination
  • MSS global programs: The Ministry of SMEs and Startups provides export vouchers, overseas market development support, and international trade show participation funding
  • KBIO global partnerships: Government-facilitated partnerships with overseas bio clusters and regulatory agencies provide introductions and technical cooperation opportunities
  • Tax incentives: Tax benefits are available for R&D expenditures related to overseas market development and regulatory submissions
  • How KITIM Can Help

    KITIM supports Korean bio companies in developing and executing overseas expansion strategies. Our services include regulatory pathway analysis, partnership identification, government funding applications for international programs, and market entry planning. Contact us to begin planning your global expansion.

    Overseas ExpansionGlobal RegulationBio Export

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.